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CD4+CD25+Foxp3+ T lymphocytes, known as regulatory T cells or Tregs, have been pro-
posed to be a lineage of professional immune suppressive cells that exclusively counteract
the effects of the immunoprotective “helper” and “cytotoxic” lineages of T lymphocytes.
Here we discuss new concepts on the mechanisms and functions of Tregs. There are sev-
eral key points we emphasize: 1. Tregs exert suppressive effects both directly on effector
T cells and indirectly through antigen-presenting cells; 2. Regulation can occur through a
novel mechanism of cytokine consumption to regulate as opposed to the usual mechanism
of cytokine/chemokine production; 3. In caseswhereCD4+ effectorT cells are directly inhib-
ited byTregs, it is chieﬂy through a mechanism of lymphokine withdrawal apoptosis leading
to polyclonal deletion; and 4. Contrary to the current view, we discuss new evidence that
Tregs, similar to otherT-cells lineages, can promote protective immune responses in certain
infectious contexts (Chen et al., 2011; Pandiyan et al., 2011). Although these points are
at variance to varying degrees with the standard model of Treg behavior, we will recount
developing ﬁndings that support these new concepts.
Keywords: tregs,Th17, immune suppression mechanism, BIM cytokine deprivation death, apoptosis, regulatoryT
cells, Foxp3, cytokine consumption
INTRODUCTION
The immune systemmaintains a delicate balance between adaptive
lymphocyte responses to foreign antigens that efﬁciently counter-
act a myriad of microbial assaults, but maintain unresponsive-
ness or “tolerance” to a large variety of harmless self-antigens.
This requires distinguishing harmless “self” (that also includes
commensal microbes) from harmful “non-self” throughout the
lifetime of the host. When this balance is disturbed, it can lead
to inﬂammatory disorders, autoimmunity, and allergy. Although
immunity involves panoply of different cell types, we will focus
principally on the control of T lymphocytes,which serve to orches-
trate most immune responses. Tolerance is achieved in part by
selecting against self-reactive T lymphocytes during ontogeny in
the thymus, a powerful mechanism termed as central tolerance
(GershonandKondo,1971;Bonomoet al., 1995;Zheng et al., 2003;
Kyewski and Klein, 2006; St Clair et al., 2007). However, there are
“peripheral” tolerance mechanisms that divert immune responses
away from self and toward appropriate pathogens (Miller and
Morahan, 1992; Arnold et al., 1993; Anderson and Chan, 2004;
Anderson et al., 2005; St Clair et al., 2007; Moraes-Vasconcelos
et al., 2008).
Peripheral tolerance can be achieved through multiple mech-
anisms affecting the survival, differentiation, and function of
effector T lymphocytes (Sprent, 1995). In this review, we will
focus on the programmed death of T cells which in the periph-
ery, accounts generally for propriocidal or autoregulatory deletion
of self-reactive cells upon chronic restimulation by self-antigens
(deletional tolerance; Lenardo et al., 1999; Sprent and Surh,
2001). Peripheral deletion can be mediated by cell death pathways
involving Fas, TNF-∝, granzymes, or passive cytokine deprivation
pathways driven by pro-apoptotic members of the Bcl-2 family
such as Bim (Chen et al., 1995; Stockinger, 1999; Strasser et al.,
2000; Bidere et al., 2006). Peripheral deletion pathways are typ-
ically clonal in that speciﬁc engagement of antigen receptors in
the T-cells activity on internal death program leading to deletion
(Lenardo, 1991;Hornung, 1997). Other mechanisms of peripheral
tolerance not discussed in this review include rendering self-
speciﬁc cells inactive (anergy), deviating the immune system to
innocuous or protective responses (immune deviation), adjusting
lymphocyte responses so that available antigen levels are below
the threshold of detection (clonal ignorance) or suppression of
local responses by biological mediators such as CTLA-4, IL-10,
and TGF-β (suppression or regulation; Schwartz, 2003; Anderson
and Chan, 2004).
Recently, a great deal of experimental work has centered on
a form of dominant tolerance mediated by a class of thymus-
derived CD4+ CD25hi CTLA-4hi Foxp3+ T lymphocytes, known
as regulatory T cells or Tregs, that appear to suppress effector T-
cell function (Sakaguchi et al., 2008). There are long-standing
antecedents to that concept. T lymphocytes regulate immune
responses both positively and negatively. Historically, a binary par-
adigm,which categorized CD4+ cells as “helpers” and CD8 cells as
“suppressors” was put forward, as soon as T cells could be distin-
guished by cell surface markers. This paradigm has had a powerful
inﬂuence on the literature of immunology (Janeway et al., 1975;
Damle, 1986). However, this concept lost ground when CD8 cells
were found to mediate protective anti-viral cytolysis and other
problems arose in the characterization of “suppressors”(Shevach,
2011). A similar binary paradigm has been reincarnated in the
past decade for CD4 cells such that Th1, Th2, and Th17 cells
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mediate immunoprotective helper (and autoimmune) functions
and CD4+CD25+Foxp3+Treg cells mediate suppressive or anti-
helper functions (Zhu and Paul, 2010). The main functions of
the helper cells are that Th1 cells express interleukin-2 (IL-2),
interferon- (IFN)-γ, and lymphotoxin (LT) or TNF-α, Th2 cells
produce IL-4 and IL-5, and Th17 cells produce IL-17A, -17F, IL-22,
and TNF-α (Bettelli et al., 2007). On the other hand, Tregs express
IL-10, TGF-β, CD25, and Foxp3 but do not produce inﬂamma-
tory cytokines under most situations (Fontenot and Rudensky,
2005). Severe atopic autoimmune conditions in scurfy mice and
immune dysregulation polyendocrinopathy X-linked (IPEX) syn-
drome patients with mutations in FOXP3, highlight the functional
importance of Tregs in suppressing severe autoimmune reactions
in mice and humans (Bennett et al., 2001).
However, less attention has been focused on the fact that
immunoprotective functions are defective when FOXP3 and pre-
sumably Treg cells are lacking (Costantino et al., 2008; Coutinho
and Carneiro-Sampaio, 2008). IPEX is a primary immunodeﬁ-
ciency because severe infections involving bacteria, viruses, and
fungi such as Candida sp. affecting a variety of organ systems con-
tribute to early mortality in IPEX patients (Moraes-Vasconcelos
et al., 2008). The immunoprotective functions of Fox P3 and
presumably Tregs have not been elucidated in detail. Recent
research has provided important new insights into the regulator
behavior of Tregs, both as suppressors and immune stimulators.
Here we discuss the molecular mechanisms governing immune
responses, especially T lymphocyte effector functions by Tregs,
with an emphasis on polyclonal deletional tolerance (Pandiyan
et al., 2007). Furthermore, we review the recent descriptions of
immunoprotective functions of Tregs including evidence for func-
tional plasticity in Tregs, depending on the immune environment
(Pandiyan et al., 2011). Finally, we suggest an alternative model of
immunoregulation and immunoprotection functions being dis-
tributed among all CD4+ T lymphocyte subtypes and each subset
has important positive and negative immunoregulatory roles.
Tregs – DISCOVERY AND FUNCTIONS
CD4+CD25+Foxp3+ Tregs [natural (n) Tregs] are thymus derived,
and constitute 5–10% of peripheral CD4 T cells. They are said
to be “anergic” because they do not express the IL-2 gene and
proliferate poorly when stimulated alone under most conditions.
The suppressive capacity of Tregs was identiﬁed in vivo by sem-
inal experiments showing that day 3 thymectomized mice and
mice depleted of Tregs succumbed to systemic autoimmunity
(Sakaguchi et al., 1982, 1996). The ability of Tregs to restrain
auto-aggressive immune reactions, led to the idea that these cells
represented a type of specialized suppressor cells. However, other
in vitro data show that addition of exogenous IL-2 and α-CD28
combined with antigen-presenting cells (APC) not only breaks
the anergic state and promotes Tregs proliferation, but also largely
abrogates the suppression effect (Takahashi et al., 1998; Thornton
et al., 2004b). This opened the door to possible immunological
roles for Tregs besides suppression, but until recently this has been
largely unexplored.
The plurality of mechanisms that have been postulated by dif-
ferent groups to explain nTregs function in different in vitro and
in vivo settings is remarkable (Shevach, 2002; Von Boehmer, 2005;
Rudensky and Campbell, 2006; Tang and Bluestone, 2008). Many
investigators detect immune regulatory effects by culturing a mix-
ture of Tregs and effector T cells in vitro (Takahashi et al., 1998;
Thornton and Shevach, 1998;Von Boehmer, 2005; Pandiyan et al.,
2007; Tran et al., 2009a). The manner in which such mixtures
are prepared and examined often leads to varied conclusions but
mainly interpreted to reinforce the preconceived binary paradigm
of helpers/suppressors. For example, the presence or absence of α-
CD28 antibodies,APC, cell density, and types of target cells in such
mixtures have led to different interpretations by different investi-
gators (Takahashi et al., 1998, 2000; Thornton and Shevach, 1998;
Pandiyan et al., 2007). Failing to take into account the experi-
mental details, such as the target cells that are suppressed, cell
density, TCR activation strength, has caused confusion and even
misleading information regarding the regulatory action of Tregs
(Takahashi et al., 1998, 2000; Thornton and Shevach, 1998; Tran
et al., 2009b). This is illustrated in the following examples.
First, one in vitro study sought to establish that Treg cells serve as
“professional”suppressor cells that shut off IL-2 gene transcription
when present during the stimulation of effector T cells, ostensi-
bly supporting the helper/anti-helper paradigm (Thornton and
Shevach, 1998). In this study, however the fate (cell death) of the
effector T cells was not examined. Later studies showed that con-
sumption of IL-2 and not IL-2 production suppression by the Treg
cells led to lymphokine withdrawal death of the effector cells indi-
cating that decreased thymidine incorporation was due to death
of the effector cells (Pandiyan et al., 2007). This is explained by the
fact that, in this conventional proliferation assay, the indicator cells
are the proliferating cells themselves and if these cells are dying,
then no conclusions can be drawn regarding the “suppression”
of proliferation. IL-2 is well-known to be regulated at both tran-
scriptional and message stability levels (Zhu et al., 2010). Since the
effector T cells die under these conditions, less steady-state mRNA
was found, but when examined, no direct suppressive effect on
the IL-2 promoter or gene transcription was found (Klein et al.,
2003; Pandiyan et al., 2007). Finally, the conclusion drawn from
these assays was that Treg cells were “professional suppressor cells”
that are solely suppressive, but no experiments were done to assess
their helper functions. The later discovery that Treg cells can pro-
mote the differentiation and cytokine production by Th17 cells in
an immunoprotective setting (described below) undermines the
binary concept of “professional” helpers and suppressors in the
CD4 T lineages. This is important because current investigations
involve injecting Treg cells as therapy for human disease based
on the professional suppressor notion. However, current ﬁndings
indicate that the injected Treg cells may have unpredictable effects
or even exacerbate disease owing to their plasticity (see below;
Zhou, 2008; Zhou et al., 2009a; Zhu and Paul, 2010; Pandiyan
et al., 2011).
Similarly, in vivo assays have led different investigators to
explain immunosuppressive effects by a variety of molecules such
as IL-10, TGF-β, IL-35, and CTLA-4 among others. IL-10 pro-
duced by Tregs, seems to be suppressive in vivo, keeping immune
responses in check at environmental interfaces of the host, such
as the colon and lungs (Klein et al., 2003; Kearley et al., 2005;
Rubtsov et al., 2008). However, it is puzzling that IL-10 produc-
tion by Treg cells is not required for the control of T cells in vitro
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(Thornton and Shevach, 1998; Takahashi et al., 2000; Rubtsov
et al., 2008). Similarly, CD4 effector T cells from TGF-β recep-
tor II (RII) deﬁcient mice have been shown to be resistant to
Treg-mediated suppression in vivo. On the other hand, evidence
showing that TGF-β deﬁcient Tregs suppress T cells in in vitro
assays and autoimmune colitis in vivo clearly, which seems to
exclude TGF-β mediated regulation as the principle suppressive
mechanism of Tregs (Shevach et al., 2001). One alternative expla-
nation is that TGF-β RII knockout (KO) T cells are intrinsically
hyperactive and less suppressible by Tregs (Wan and Flavell, 2007).
TGF-β RII KO CD4 cells may produce abnormally high levels
of cytokines causing them to be refractory to cytokine depriva-
tion death. Thus, TGF-β seems unlikely to directly mediate Treg
suppression. TGF-β produced by natural Tregs may convert con-
ventionalCD4Tcells into Foxp3 expressing“induced”Tregs (iTregs;
Andersson et al., 2008; Pandiyan and Lenardo, 2008; Shevach et al.,
2008). These iTregs have suppressive functions and may confer
“infectious tolerance” since they can be induced or recruited to
spread tolerance (Shevach et al., 2008). However, the exact mech-
anism of how they suppress is unknown. Similarly, IL-35, a novel
member of the IL-12 family, also contributes to Treg-mediated
infectious tolerance by converting conventional T cells into Tregs
(Collison et al., 2010). However, the presence and function of IL-
35 in human CD4+ Foxp3+ Tregs is controversial (Bardel et al.,
2008; Chaturvedi et al., 2011; Liu et al., 2011). Moreover, EBI-3
(IL-35) KO mice do not exhibit gross autoimmunity similar to
that displayed by Foxp3, IL-2 or CTLA-4 deﬁcient mice, raising
a question about its physiological role in Tregs function (Bardel
et al., 2008; Chaturvedi et al., 2011; Dokmeci et al., 2011; Liu
et al., 2011). Finally, although CTLA-4 was originally claimed not
to be required for the suppressive mechanism of Tregs in vitro, as
described below, new evidence clearly supports a role in modu-
lating APC function which will indirectly inhibit T-cell activation
under certain circumstances (Wing et al., 2008; Qureshi et al.,
2011). The contradictions in these data appear to result from
the classic “blind men and the elephant” effect. Different groups
have examined only selected aspects of the multi-step process of
suppression. Taken together, Tregs deploy different mechanisms
of regulation depending on the immunological context, location,
conditions of T-cell activation and differences in target cells (She-
vach, 2002; Von Boehmer, 2005; Rudensky and Campbell, 2006;
Tang and Bluestone, 2008).
Recently, a few mechanisms of Tregs action have become
increasingly clear. We will brieﬂy describe two negative effects on
T effector responses – mediated by the high afﬁnity IL-2 receptor
(IL-2R) and the CTLA-4 molecule – and one positive effect on T
effector responses mediated by the high afﬁnity IL-2R.
NEGATIVE EFFECTS OF Treg CELLS
The negative effects are mediated, not surprisingly, by two cell sur-
face “receptors” that are expressed extraordinarily highly on Treg
cells – IL-2R (CD25) and the CD152 (CTLA-4) receptors. In order
to understand the immunosuppressive effect of Tregs in vitro, it is
important to distinguish the direct impact on T-cells mediated by
IL-2R and indirect inhibitory effects on APC mediated by CTLA-
4 (Pandiyan et al., 2007; Sakaguchi and Wing, 2011; Wing et al.,
2011).
IL-2 CONSUMPTION AND CYTOKINE DEPRIVATION
APOPTOSIS IN CD4 T CELLS
A deﬁning feature used in the initial isolation of Treg cells was a
characteristically high level of expression of CD25. It was therefore
surprising that TCR stimulation of Treg cells led to no produc-
tion of IL-2 under most circumstances. This led us and others to
hypothesize that theCD25 (IL-2R) served an important regulatory
function for Treg cells. One of the most important characteristics
of nTregs is the requirement of IL-2 for their suppressive func-
tions (Scheffold et al., 2005). Scheffold and Stockinger’s groups
demonstrated that Tregs consume IL-2 to exert their suppressive
functions (Barthlott et al., 2003; De La Rosa et al., 2004). Starting
from these observations, we investigated whether consumption of
IL-2 is an actual suppressive mechanism for immune responses
by Tregs. We also recognized that none of the studies on Treg sup-
pression had determined the fate of the “suppressed”CD4 effector
cells, especially in the in vitro assay systems, However, apoptosis
and cell survival were well-known immune regulatory mecha-
nisms (Lenardo et al., 1999). Therefore, we examined the direct
effects of Tregs on CD4 T cells and the fate of the “suppressed”
T cells (Pandiyan et al., 2007). We observed that Tregs consume
a large fraction of the IL-2 that is produced by the stimulated
CD4 responder cells (effector cells). Tregs produce no IL-2 them-
selves even though their survival depends on it. Close proximity
of a large number of Treg cells deprives the effector CD4 cells of
this primary growth factor causing proliferation arrest and apop-
tosis of both cell populations (Pandiyan et al., 2007). This effect
could quantitatively explain the drop in proliferation measured
by tritiated thymidine incorporation described in earlier studies
(Thornton and Shevach, 1998) and did not require the presence of
APCs. Thus, Tregs directly regulate the IL-2 producing Th0 effec-
tor cells through a chain of events leading to IL-2 deprivation
and polyclonal deletion (PCD). The deletion is “polyclonal” at
least according to in vitro experiments, because the suppression
does not depend on any clonotype speciﬁcity of Tregs and target
cells consistent with prior evidence that Tregs “suppression” is not
antigen speciﬁc in most settings (Thornton and Shevach, 2000;
Sakaguchi et al., 2008).
Cytokine deprivation happens at two levels. First, Tregs directly
consume growth cytokines secreted at early phase of activation
by effector T cells that are in the immediate vicinity at early
phase of activation. Close juxtaposition is crucial for intercep-
tion of IL-2 in its autocrine loop of production and utilization
by effector T cells. Second, they cause failure of activated cells to
produce cytokines at a later phase of activation by removing a
critical IL-2 positive feedback (Pandiyan et al., 2007). In Th0 cells,
a powerful positive feedback loop is initiated by IL-2 production
during early T-cell activation, in which autocrine IL-2 induces
the high afﬁnity IL-2R expression rendering activated T cells to
react more efﬁciently with IL-2. This leads to the production of
other T-cell cytokines and proliferation. Signaling by early IL-
2 is essential for later optimal cytokine production and effector
functions. By consumption of IL-2, Tregs can effectively inter-
rupt these processes by down-regulating IL-2R expression and
dampening further cytokine expression and proliferation. Thus,
suppression of proliferation and death due to cytokine depriva-
tion may have a more pronounced effect on effector and effector
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memory T-cell populations. Further investigations elucidated the
importance of TCR stimulation strength in the processes of IL-
2 consumption and Treg suppression (Tran et al., 2009b). These
experiments demonstrated that human Tregs consume mouse IL-
2, which inhibits mouse effector T cells at mid range but not at
very strong stimulation conditions. We also ﬁnd that in human
Tregs, consumption causes PCD under low dose α-CD3 stim-
ulations and not at high α-CD3 concentrations (Pandiyan and
Lenardo, unpublished results). However, the minimum amount
of IL-2 that must be consumed to obtain PCD, how TCR sig-
nal strength affects IL-2 consumption, other cytokines that might
alter the IL-2 consumption rate and the suppression processes,
and how IL-2 consumption may affect APCs, remain to be investi-
gated. It seems intuitive that low strength TCR stimulation is more
reﬂective of an immune response to the low-afﬁnity self-antigens
in vivo and therefore, PCD may play a predominant role in such
an immune context. In addition to direct cytokine consumption,
whether Bim-dependent apoptosis may also be caused by TGF-β
remains to be addressed (Ramesh et al., 2008; Houde et al., 2009;
Sanjabi et al., 2009; Tinoco et al., 2009). However, more work is
needed to address these important questions, which will facilitate
our understanding of how Tregs and PCD can be therapeutically
deployed.
CYTOKINE DEPRIVATION VERSUS OTHER DELETION
MECHANISMS IN CD4 T CELLS
The consumption of available IL-2 by Tregs plays a key role in
PCD of responder T cells but other cytokines in vitro and in vivo
may be involved (Pandiyan et al., 2007). The biochemical events
were PI-3 kinase inactivation, Akt/BAD dephosphorylation and
Bim-dependent apoptosis. This was veriﬁed by removing the Bim
apoptosis gene in effector T cells, and examining their response to
suppressive effects in co-cultures with wild-type Tregs. The Bcl-2
family member Bim is a central mediator of intrinsic apoptosis
pathways, orchestrating cytokine withdrawal apoptosis in vari-
ous hematopoietic cells that depend on trophic cytokines for
growth and survival (Hildeman et al., 2002). In particular, it
mediates lymphocyte death caused by cytokine deprivation gen-
erally at the end of immune responses (Hildeman et al., 2002).
Bim knockout (KO) mice suffer with lupus-like autoimmunity
and kidney disease due to defective apoptosis of T and B cells
(Strasser, 2005). We found that Bim-KO effector T-cells clearly
resist suppression by fully active Tregs and are not impaired in
late-phase cytokine production. Hence, “suppression” was abro-
gated by removal of an apoptosis gene in the effector T cells that
were the target of wild-type Tregs. Unaffected cytokine production
in Bim-KO cells implies that the late-phase cytokine suppres-
sion resulted from the death of cytokine producers. These data
validate the hypothesis that Treg cells can regulate cytokine depen-
dent homeostatic proliferation of effector T cells by killing them
in an antigen non-speciﬁc manner in vivo. This was demon-
strated by the ability of Treg cells to suppress inﬂammatory bowel
disease (IBD) in a mouse model, in which the disease is par-
tially driven by homeostatic proliferation of naïve CD4 cells
in a lymphopenic environment (Powrie et al., 1994). However,
Treg cells failed to suppress IBD caused by Bim-KO cells. This
indicates that direct cytokine deprivation and BIM-dependent
apoptosis by Tregs plays a signiﬁcant role in their ability to regulate
IBD.
Polyclonal deletion mediated by natural Treg cells apparently
does not involve direct cytolytic mechanisms such as activation
of Fas or cell contact-dependent, granzyme-mediated cell death
(Takahashi et al., 2000; Pandiyan et al., 2007). We found no evi-
dence of death mechanisms mediated by TNF receptor family
members or perforin and/or granzymes.Moreover, our data show-
ing that PCD of the CD4 T-cells occurred slowly (3–4 days after
activation) argues against the direct cytolysis mechanism, which
usually kills the target cells within 24 h. Our studies also support
the idea that close proximity, not necessarily direct physical con-
tact, is crucial for Treg cells to compete effectively for cytokines
produced by the effector T cells or APCs and thereby block the
autocrine and paracrine loops that are essential for effector T-cell
survival, proliferation, and cytokine production (Scheffold et al.,
2005; Busse et al., 2010). Although the exact distance required
between target cells and Treg cells for efﬁcient IL-2 consumption
is currently unknown, we believe that the closer the proximity of
the two cells, the more likely it will be that the IL-2Rs on the Tregs
will compete better to capture the IL-2 produced by the effector T
cells before it can interact with the IL-2Rs on the T effector cells
themselves.
It has been shown that Treg cells can block the autoimmune
disease that occurs in IL-2 KO mice (Schimpl et al., 2002). Along
with our results showing that Treg cells kill IL-2 KO T cells in vitro,
it raises a possibility that Treg cells can cause PCD by consuming
cytokines besides IL-2. In fact, at this point it is unclear consump-
tion of which cytokine contributes themost to the immunoregula-
tory properties of Tregs. Because Treg cells are themselves heavily
dependent on common gamma (γc)-chain cytokines, it is likely
that in the absence of IL-2, they will consume/regulate other γc-
chain cytokines to gain control of activated CD4 cells (Pandiyan
and Lenardo, 2008). We found that the addition of γc-chain
cytokines such as IL-4, IL-15, and others to the Treg/effector T-cell
co-culture can completely rescue effector T cells from apoptosis,
conﬁrming that a variety of cytokines can tip the survival balance
(Pandiyan et al., 2007). Cytokine/s that drive the proliferation of
the IL-2 KOCD4T cells in the absence of IL-2, how that cytokine is
regulated by Tregs, and howAPCs are affected in cytokine deprived
situations in vivo, are questions that remain to be answered.
Although Tregs mediate the PCD of activated effector CD4+ T
cells, extensive experimentation shows they do not suppress prim-
ing or initiation of T-cell receptor (TCR) activation and/or early
IL-2 production in T cells (Thornton et al., 2004a; Oberle et al.,
2007; Pandiyan et al., 2007; Esquerre et al., 2008). This contradicts
a tenet of Treg suppression proposed in previous studies (Thorn-
ton and Shevach, 1998). Early IFNγ and IL-2 gene expression is
not affected bymouse Tregs in conventional co-cultures, so that the
simplistic paradigm of helper/anti-helper competition to control
early activation events fails to explain T effector cell regulation by
Tregs (Pandiyan et al., 2007). This conclusion is reinforced by the
fact that in human T cells, early TCR signaling events and cal-
cium mobilization in effector T cells are unaffected by Treg cells
(Esquerre et al., 2008). Further experiments have demonstrated
that the proliferation (and survival) of previously activated effec-
tor T cells are susceptible to Treg suppression, indicating that Treg
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cells do not need to affect initial priming of mouse T cells in
order to suppress them in vitro (Pandiyan et al., 2007; Esquerre
et al., 2008). Moreover, cytokine deprivation and Bim regulates
the survival of Tregs themselves, and, in the absence of gamma
chain cytokines, they die by apoptosis (Pandiyan and Lenardo,
2008). During an immune response, early production of IL-2 dri-
ves activated T cells into proliferation and at the same time makes
the proliferating T-cells totally dependent on IL-2 (Lenardo et al.,
1999). Intact early activation events andnormal effectorT-cell pro-
liferation are therefore essential for the IL-2 consumption made
of PCD by Treg (Klein et al., 2003). Although Tregs can modu-
late APCs, we have found that potent Treg suppression of effector
T cells by PCD occurs in the absence of APCs in vitro. Taken
together, direct induction of PCD in activated and cycling T-cells
plays a major role in the Treg-mediated immune suppression but
not direct impairment of naïve T cells or any direct effect on early
T-cell activation.
MODULATION OF APC BY Tregs ALSO CONTRIBUTES TO
SUPPRESSION
A second mode of negative regulation is the effect of Tregs on
APC such as dendritic cells. When Tregs are mixed with APCs
and then the APCs are isolated and used to stimulate T cells,
theseAPCs function suboptimally inmany conditions.Hence,Treg
effects onAPC’s could indirectly affect T-cell responses. Consistent
with the idea of APC regulation, CTLA-4, which is constitutively
expressed on Tregs, has been found to indirectly regulate T cells
by down-regulating co-stimulatory molecules such as CD80 and
CD86 on APC (Wing et al., 2008). Initially, this effect was some-
what mysterious, but elegant studies showed that CTLA-4 could
capture its ligands from opposing cells, by a process of trans-
endocytosis. This reduces the level of CD80 and CD86 on the
APCs in the immediate vicinity, which will reduce co-stimulation
provided to the effector T cells (Qureshi et al., 2011). Treg-speciﬁc
CTLA-4 deﬁciency impairs in vivo and in vitro suppressive func-
tion of Tregs (Wing et al., 2008). In vitro blocking experiments
with anti-CTLA-4 antibodies give less clear-cut results because
of low/transient CTLA-4 binding at the cell surface. The role
of APC modulation is further supported by the studies demon-
strating that Treg cells could regulate the contact and clustering
between APC and T cells (Tadokoro et al., 2006; Tang et al., 2006;
Qureshi et al., 2011). Thus, strong evidence now indicates that
Tregs inhibit immune responses by directly blocking the survival
and effector functions of CD4 cells and indirectly by down-
modulating APC co-stimulation. These new observations provide
a compelling mechanism, but further validation by other groups
and more information about the speciﬁcity and kinetics of the
CTLA-4 transcytosis will be necessary. However, CTLA-4 and IL-
2-dependent suppression can be regarded as core mechanisms of
Treg-mediated suppression, explained by the high levels of CTLA-4
and CD25 (IL-2R) characteristically expressed by Tregs (Sakaguchi
et al., 2009).
COORDINATION BETWEEN DELETION OF T CELLS AND
OTHER MECHANISMS OF SUPPRESSION IN VIVO
Consumption of cytokines and PCD of effector T cells by Tregs
plays an important role in reducing the strength of the immune
response in vivo (Pandiyan et al., 2007). We speculate that in the
initial phase of an immune response, the effector T:Treg ratio is
higher because effector T cells are proliferating faster than Tregs.
However as the response progresses, Tregs consume IL-2 from
activated cells, proliferate, and cause accelerated apoptosis of IL-
2-dependent effector T cells. This begins to shift the effector T:Treg
balance. Bim-dependent PCD of a substantial number of cytokine
producing CD4 cell progenitors in the initial phase of the response
inhibits further cytokine production by affecting differentiation of
CD4 effector T cells into Th1, Th2, or Th17 effectors (due to poor
expression of cytokines and cytokine receptors; Figure 1). These
forces all act together to reduce the number of speciﬁc effector T
cells, to dampen the immune response.
Thus, PCD directly reduces the intensity of an immune
response by tapering the T-cell population, and the diminished
population of effector cells is rendered more susceptible to other
suppression mechanisms (Tang and Bluestone, 2008; Figure 1).
The suppressive factors could directly be produced by Tregs, or
indirectly induced in other cells by Tregs. Cytokine consump-
tion ensures loss of effector functions in the remaining effector
population making them immunologically inactive and restores
Treg numbers for future regulation. Even though we believe that
suppression of late cytokine production is chieﬂy caused by the
“disruption of cytokine positive feedback loop,” the effects of
other postulated mechanisms could be important. Cytokines pro-
duced during effector response may further potentiate Tregs to
produce other suppressive or even non-suppressive factors (see
below). For example, IL-2 may trigger transcriptional events lead-
ing to the expression of IL-10, TGF-β, EBI-3, or IL-35 in Tregs
(Maloy and Powrie, 2005). These suppressive molecules further
reduce inﬂammation by inhibiting effector CD4 cells, as well as
modulating APC and other inﬂammatory cells. Furthermore, Treg
dependent Foxp3 and IL-35 induction in effector T cells may also
contribute to their intrinsically impaired cytokine production at
later phases (Andersson et al., 2008; Pandiyan and Lenardo, 2008;
Collison et al., 2010). The speciﬁc role of each mechanism in sup-
pressing a heterogeneous population of effector Th1, Th2, and
Th17 cells in vivo remains to be seen. Deprivation of cytokines
and induction of apoptosis by Tregs could differentially affect tar-
get cell functions, depending on whether the immune response
is pro- or non-inﬂammatory, or whether the immune cells are
responding to microbial infections or self-antigens. The phase
(early versus late) of the immune response and the correspond-
ing cytokine environment also likely dictate the functions of Tregs.
Thus, these suppressivemechanismsmayplay their distinct roles in
the multi-step process of immune suppression at different stages.
ARE Foxp3+ CD4+ CELLS SOLELY DEVOTED TO TOLERANCE?
There is great deal of literature correlating Foxp3 expression in
CD4 cells with active immune suppression. However, recent evi-
dence indicates that Foxp3+ cells may play other immunological
roles (Komatsu et al., 2009; Zhou et al., 2009b; Chen et al., 2011;
Pandiyan et al., 2011). Although Foxp3+ CD4+ Tregs have sup-
pressive capability, Foxp3 expression in CD4 cells may not always
indicate suppression. Tregs may have positive immune functions
and this possibility has been explored much less because of the
preconception that they are simply “suppressor” cells. Transient
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FIGURE 1 |Treg-mediated apoptosis plays a major role in limiting
Th07Th1/Th2 cell responses. Under steady-state conditions, CD4+ T cells
upon priming, produce IL-2 and /or other growth factors and expand
responding to these cytokines. If Tregs are present during this early phase of
IL-2 production, CD4+ T cells are deprived of IL-2 leading to CD4+ T-cell death.
However, cells that are not in direct/close proximity to Treg5, may remain in the
system and continue to expand. Because of the low levels of IL-2 in their
milieu and inactivation of APC by CTLA-4, their later effector function and
cytokine production are impaired. This limits autoimmunity, perhaps under
homeostatic conditions involving self-antigens.
expression of Foxp3 in a subset of activated cells or in TGF-β-
induced iTregs does not necessarily mean that these cells can func-
tion like-thymus-derived suppressive “natural” Treg cells (Hoff-
mann et al., 2009; Huehn et al., 2009; Komatsu et al., 2009; Lahl
et al., 2009; Thornton et al., 2010). Also, Foxp3 alone does not
control all the elements of Treg signature phenotype (Zhou et al.,
2008). The presence of Foxp3+ cells in vivo may reﬂect an inﬂam-
mation that has induced Foxp3 expression in activated cells (iTregs)
or proliferation of natural Tregs, and not necessarily associated
with active suppression of immune responses. Similar to Tregs
induced in vitro (iTregs), a subset of natural Tregs might represent a
population with unstable Foxp3 expression in vivo. Given the plas-
ticity of Tregs and Foxp3 expression in activated cells, care should
be taken when interpreting the data from experiments involving
Foxp3 positive cells in disease conditions.
Although controversial, recent accumulating evidence shows
that Foxp3+ Treg cells can themselves become effector cells or
produce cytokines under strong pro-inﬂammatory conditions
(Komatsu et al., 2009; Zhou et al., 2009b; Rubtsov et al., 2010).
In some instances they are even shown to exacerbate pathogenic
immune responses (Zhou et al., 2009a,b). It has been observed
in an experimental allergic encephalomyelitis (EAE) model, that
Ag speciﬁc Tregs accumulate in brain but fail to control inﬂam-
mation (Korn et al., 2007). This raises an interesting possibility
that Treg functions are not limited solely to suppression but also
to other effector functions, including protection against infection.
Evidence to support this idea emergedwith the demonstration that
Tregs play an important role in controlling lethal West Nile virus
(Lanteri et al., 2009). Those functions may be largely dependent
on cytokine milieu or innate immune responses.
We and others have shown that under Th17 milieu, IL-2 con-
sumption by Tregs actually leads to an enhanced proliferation and
cytokine production of early Th17 cells in vitro and in the context
of oral Candida infection or inﬂammation in vivo (Chen et al.,
2011; Pandiyan et al., 2011). IL-2 has been known to inhibit Th17
differentiation. By enhancing Th17 cells, these non-suppressive
Tregs reduce the fungal burden in mice (Pandiyan et al., 2011;
Figure 2).Moreover,our preliminary studies show thatTregs them-
selves lose Foxp3 in Th17 inﬂammatory conditions in vitro, which
also likely contributes to the loss of their suppressive properties
(unpublished results). These destabilized Tregs (Ex-Tregs) are only
present transiently, because in a chronic Th17 IBD model, such
Ex-Tregs can regain suppressive functions and show a delayed, but
strong potential to suppress Th17 inﬂammation (Pandiyan et al.,
2011). The mechanism of reacquisition of suppressive properties
by Tregs and the mechanism of the delayed suppression of Th17
cells remain to be investigated. The loss of suppressive functions
in Tregs during infections might be associated with certain toll like
receptor (TLR) ligands and strong responses through massive pro-
duction of inﬂammatory cytokines (Pasare and Medzhitov, 2003).
Thismechanismmight allowprotective immune responses against
microbes to proceed normally. Thus, Foxp3+ Tregs could be prin-
cipally suppressive when inﬂammatory cytokines are low, such as
during late-phase responses, which prevents immunopathology in
the host. However, they may not be destined solely for suppressive
functions, because they also act as helper cells to promote certain
immune responses in cytokine-rich environments, such as during
infections (Pandiyan et al., 2004; Zhou, 2008; Lanteri et al., 2009).
Taken together, Foxp3+ cells may represent a subset of protective
immune cells like T helper cells, but with elaborate suppressive
capacities.
Even T helper cells such as Th1, Th2, and Th17 cells can be
regarded to possess regulatory potentials. These cells along with
Th22 cells and inducible regulatory T cells such as Foxp3+ iTregs
and iTr35 (the inducible regulatoryT-cells expressing IL-35) polar-
ize under speciﬁc cytokine milieu along with TCR stimulation.
(Yang et al., 2008; Bluestone et al., 2009; Lohr et al., 2009; Bending
et al., 2011; Hirota et al., 2011). For example, under a Th1 skewing
condition, IFN-γ and IL-12 activate signal transducer and activa-
tor of transcription 4 (STAT4) and STAT1, leading to the activation
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FIGURE 2 |Treg cells promoteTh17 cells at early phase and
modulate inflammatoryTh17 responses at later phases. Under
Th17 inﬂammatory conditions, CD4+ T cells and expand responding to
factors such as IL-21 and IL-6. Tregs do not inhibit the survival or proliferation
of those cells becauseTh17 cells produce excess of IL-2, IL-21, IL-6, and
TNF-α, all of which overcome the suppression by cytokine deprivation. Some
Tregs also lose Foxp3 expression (Ex-Treg), which also likely contributes to the
absence of suppression. However, Tregs enhance IL-17 production by
consuming IL-2. This promotes clearance of pathogens that require protective
Th17 responses. However when the cytokine levels drop at later phases, Tregs
limit Th17 cells, likely by other mechanisms such asTGF-β and APC modulation
by CTLA-4.
of T-bet, a transcription factor and a master regulator for Th1
differentiation (Ashkar et al., 2000; Glimcher and Murphy, 2000;
Szabo et al., 2000). Along with Runx3 activation, a positive feed-
back loop forms and accelerates the expressionof theTh1hallmark
cytokine IFN-γ. Meanwhile, activated T-bet and Runx3 can sup-
press GATA3 signaling, causing the expression of the Th2-speciﬁc
IL-4 gene to be inhibited (Hegazy et al., 2010; Zhu and Paul, 2010).
Inhibition of Th2 factors is critical for the maintenance of Th1
cells. On the other hand, IL-4 and IL-2 are the major cytokines
that promote Th2 differentiation (Ben-Sasson et al., 1990; Le Gros
et al., 1990). Through stimulating respectively STAT6 and STAT5,
IL-4 (also produced by DC) and IL-2 activate GATA3, a master
regulator of Th2 cell differentiation, and then promote IL-4 gene
expression (Ouyang et al., 2000;Hofer et al., 2002; Tykocinski et al.,
2005). Activated GATA3 also inhibits Runx3 and thereby turns off
IFN-γ gene expression in order to suppress Th1 and augment Th2
differentiation (Yagi et al., 2010). This phenomenon, where one
type of cytokine milieu favors a lineage of T helper cell differenti-
ation, is always accompanied by suppression of the other lineages.
(Mosmann andCoffman, 1989a,b; Paul and Seder, 1994; Seder and
Paul, 1994; Zhu and Paul, 2010). This process can also be called as
cross regulation. The induction versus suppression of differentiat-
ing CD4 T-cells appears to be dependent on available cytokines in
the microenvironment of any given immune response. Although
most of the available data indicate that inhibition of transcription
factors during Th differentiation occurs in the same cell, we spec-
ulate that it is likely to occur through cytokines at intercellular
level as well. For example, differentiated Th1 cells may suppress
Th2 cells and vice versa. It will be interesting to study the cross reg-
ulation of well-differentiated Th1 or Th2 cells. In essence, while
the differentiated helper T cells can assist in mounting appropriate
immune responses, the same “helper” cells can exercise functions
of suppression, at least on some differentiating T cells. Thus, most
immune cells may harbor both immunosuppressive and immune
promoting functions and immune suppression function may not
be conﬁned to speciﬁc subsets.
A recent example that supports this tenet is the identiﬁcation of
Foxp3+ suppressive macrophages (Zorro Manrique et al., 2011).
Historically, macrophages are regarded as effector cells, classical
APCs and one of the ﬁrst responders in an immune response.
Now, it has been shown that under certain conditions they can be
suppressive in function. More importantly, we have also shown
that even effector CD4 T cells with no Foxp3 expression can
suppress CD4 T cells by consuming IL-2. These “pseudo-Tregs,”
mimic nTregs in expressing CD25 and being dependent on IL-2,
but being unable to produce IL-2 (Pandiyan et al., 2007). There-
fore, “helpers” and “suppressors” should be regarded as relative
terms; suppressive properties can reside in cells that are conven-
tionally conceived as effector/helper cells. The dose of antigens, site
of action, timing and cytokine milieu may dictate the function of
the immune cells,whether“immunosuppressive”or“immunepro-
moting.” This explains why Foxp3+ CD4+ cells regulate Th1 and
Th2 functions by cytokine deprivation but promote other types
of responses such as the Th17 response, which in and of them-
selves may regulate each other. Thus, the binary model in which
Foxp3+ CD4+ cells are exclusively suppressive and other effector
T helper cells function exclusively to promote immune responses,
may not explain all immune functions. Ultimately, coordination
between suppression of certain cells and enhancement of certain
other effector cells leads to appropriate immune responses.
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CONCLUSION
In an optimal immune response by CD4 cells, mixture of Th1,
Th2, and Th17 effector cells are generated and the dominant pop-
ulation in a given response varies. Treg cells are probably equipped
mainly to kill IL-2-dependent Th0/Th1 cells but not all the effec-
tor cells equally. Importantly, Tregs promote (and clearly do not
suppress) Th17 responses during acute inﬂammation. Thus the
function and stability of Tregs can depend largely on the immuno-
logical milieu in which they are operating. These parameters
are complex and therefore it is important to identify the sig-
nals that regulate the function of Foxp3+ Tregs and other Th
cells and determine how they cross regulate each other at the
molecular level. Regarding the overall suppression, PCD of T-
cells combined with suppression of APC by CTLA-4 and other
suppressive mechanisms ensures more stringent control of dif-
ferent T-cells subsets. The cytokine milieu and the target effector
cells that are suppressed determine the predominant mechanism
employed by Tregs in a particular immune response. The tem-
poral and spatial parameters that determine which mechanism
predominates suppression by Tregs and what is the sequence in
which the core mechanisms, i.e., cytokine deprivation and reg-
ulation by CTLA-4 are employed remain to be studied. Relative
contribution of each of the mechanism of suppression by Tregs
and when Tregs lose their suppressive properties remain to be
the important questions for future investigations. When plan-
ning strategies for intervention of immune-related disorders using
Tregs, cellular and cytokine networks as a whole, and not the
function of a single subset of cells, should be taken into con-
sideration. This is a fascinating area of research and warrants
vigorous investigation, given its potential implications in chronic
inﬂammation.
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